Aurion Biotech to Present at ESCRS and Ophthalmology Futures European Forum
Aurion Biotech announced its upcoming participation in the 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), September 6-10, 2024, in Barcelona. The company will showcase clinical data on its allogeneic cell therapy drug candidate, AURN001. Aurion will also participate in the Ophthalmology Futures European Forum, taking place on September 5.
"We are thrilled to share clinical findings, as well as key milestones in both clinical and business developments, during multiple sessions at ESCRS and the Ophthalmology Futures European Forum," Dr. Michael Goldstein, President and Chief Medical Officer of Aurion Biotech, said in a company news release. "The safety and efficacy data from the Escalón clinical trial provide further understanding of how AURN001 may offer hope for patients suffering from corneal endothelial dysfunction."
Presentations at ESCRS 2024 and Ophthalmology Futures Forum
Aurion Biotech’s team will be featured in a series of presentations and panel discussions at both events, highlighting the company's advancements in regenerative medicine and eye care.
Ophthalmology Futures European Forum
Will Novel Dry Eye Therapies Really Make a Difference?
Date: Thursday, September 5, 2024
Time: 1:15 p.m. – 1:45 p.m. CET
Location: The Esferic, Barcelona
Panelist: Dr. Michael Goldstein, MD, MBA
Cell, Gene, and Other Novel Corneal Therapies: Outlook for the 21st Century
Date: Thursday, September 5, 2024
Time: 1:45 p.m. – 2:15 p.m. CET
Panelist: Greg Kunst, CEO
Transformational Cell Therapy for Corneal Endothelial Disease
Date: Thursday, September 5, 2024
Time: 2:30 p.m. – 3:15 p.m. CET
Presenter: Greg Kunst, CEO
ESCRS iNovation Day
Transformational Cell Therapy for Corneal Endothelial Disease
Date: Friday, September 6, 2024
Time: 11:26 a.m. – 12:23 p.m. CET
Presenter: Greg Kunst, CEO
ESCRS 2024 Congress
Human Corneal Endothelial Cell Transplantation Combined with Cataract Extraction
Date: Sunday, September 8, 2024
Time: 1:15 p.m. – 1:45 p.m. CET
Presenter: Dr. Michael Goldstein, MD, MBA
Escalón: 12-Month Safety and Efficacy Clinical Trial of Human Corneal Endothelial Cell Therapy
Date: Monday, September 9, 2024
Time: 5:30 p.m. – 5:36 p.m. CET
Presenter: Dr. Michael Goldstein, MD, MBA
Consistency of Outcomes with Injectable Human Corneal Endothelial Cell Therapy
Date: Monday, September 9, 2024
Time: 5:36 p.m. – 5:42 p.m. CET
Presenter: Eris Jordan, OD, VP of Global Clinical & Medical Affairs
Regulatory Milestones
Aurion Biotech's AURN001 has received Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation from the FDA for treating corneal edema secondary to corneal endothelial disease. In Japan, Aurion has secured regulatory and reimbursement approval for treating bullous keratopathy, marking the world’s first approval of an allogeneic cell therapy for corneal endothelial disease.